Back
Mark L. Vandewalker, MD
Respiratory Research Experience
Asthma
Teva An open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of fluticasone Propionate/Albuterol Sulfate(Fp/ABS) Multidose Dry Powder Inhaler With e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants With Asthma (4 to 11 Years Old) / Pediatric Asthma
AstraZeneca A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma Adult Asthma
GlaxoSmithKline A Randomized, double-blind parallel group, multi-center study to evaluate the long-term safety of salbutamol rescue medication whe administered via metered dose inhalers containing the propellant HFA-152a or reference HFA-134a Adult/Adolescent Asthma
Exhale-4 A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma Adult/Adolescent Asthma
GlaxoSmithKline A Phase 3 24-week, Randomized, Double-blind, Parallel Group Bayesian Dynamic Borrowing Study comparing the Efficacy, Safety, Tolerability and Pharmacokinetics of FF/UMECM with FFM in 12-17 year-old Participants with Inadequately Controlled Asthma on Stable Maintenance Therapy with ICS/LABA Young Adult/Child Asthma
Cipla A Multicenter, Randomized, Parallel-Group, 6-Week Treatment Clinical Study to Assess Bioequivalence of Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg Inhalation Product (Cipla Ltd.) in comparison with the Reference Product, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate, 80/4.5 µg per Actuation) Inhalation Aerosol (AstraZeneca, USA), in Adult Asthma Patients. Adult Asthma
AstraZeneca A Randomized, Double-blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS) Adult/Adolescent Asthma
AstraZeneca A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler ®in Participants with Inadequately Controlled Asthma (VATHOS) Adult/Adolescent Asthma
Chiesi (Force 2) A 12-week, Randomized, double-blind, Multicenter, Active Controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24µg total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800µg total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. Adult/Adolescent Asthma
AstraZeneca A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Phase 3b Study to Evaluate the Potential Effect of Tezepelumab on the Humoral Immune Response to the Seasonal Quadrivalent Influenza Vaccination in Adolescent and Young Adult Patient with Moderate-to-Severe Asthma (VECTOR) Young Adult/Child Asthma
Novartis - A 12-week, randomized, participant-and investigator-blinded, placebo-controlled, parallel group study to explore the efficacy, pharmacodynamics, safety, and pharmacokinetics of two doses of inhaled CSJ117 in adults with Chronic Obstructive Pulmonary Disease (COPD) / Adult Asthma
TEVA A Phase 2, Multicenter, Rancomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of
TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma. Adult Asthma
Chiesi - A phase III, 52-week, Multinational, Multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with chronic obstructivepulmonary disease. (COPD)
Denali - A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma. Adult/Child Asthma
Novartis - A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients 18 Years of Age With Severe Uncontrolled Asthma. Adult Asthma
Teva - A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg (Supplied by Teva Pharmaceuticals Ireland) to ADVAIR DISKUS® 100/50 (fluticasone propionate/salmeterol) Inhalation Powder, (GlaxoSmithKline) in Subjects With Asthma® / Adult/Adolescent Asthma
TEVA/Compleware - A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma / Adult Asthma
TEVA/Novum - A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma Adult/Adolescent Asthma
GlaxoSmithKline - Phase IV An open-label study to evaluate correct use and ease of use of the ELLIPTA Dry Powder Inhaler (DPI) in pediatric patients currently receiving inhaled therapy for treatment of their asthma / Pediatric Asthma
Cipla - A Multicenter Randomized, Parallel-Group, Placebo-Controlled, 4-week Clinical endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 ug Inhalation Powder With Advair Diskus 100/50 ug in Asthma patients / Adult Asthma
West Ward Columbus, Inc/Pharm-Olam International - A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma / Adult/Adolescent Asthma
Pearl - A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma / Adult/Adolescent Asthma
Novartis - A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of care asthma therapy in patients with uncontrolled asthma / Adult/Adolescent Asthma
Novartis - A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of care asthma therapy in patients with uncontrolled asthma / Adult/Adolescent Asthma
Chiesi - An 8-week, randomized, double-blind, placebo and active-controlled, parallel group, dose ranging study to evaluate the efficacy and safety of 3 doses of CHF 718 pMDI (beclomethasone dipropionate) in asthmatic subjects / Adult Asthma
Lupin - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study to Assess the Efficacy and Safety of Twice Daily Administration of Fluticasone Propionate and Salmeterol Inhalation Powder 100/50 mcg Compared to Administration of ADVAIR DISKUS® 100/50 mcg Twice Daily and Placebo in Patients 12 Years of Age and Older with Reversible Persistent Asthma including a 3-Week Open-Label Extension to Assess Inhaler Robustness Asthma / Adult/Adolescent Asthma
3M - A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Inhaler and a Symbicort® Reference Inhaler, Each Delivering Budesonide/Formoterol Fumarate (80 μg/4.5 μg) in Adult Subjects With Asthma / Adult Asthma
TEVA - A 12-week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years with Persistent Asthma / Adolescent Asthma
GlaxoSmithKline - A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Propionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhaled corticosteroid and long-acting beta2 agonist./
Adult/Adolescent Asthma
Merck - A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate / formoterol fumarate (MF/F, MK-0887A [SCH418131]), compared with mometasone furoate (MF, MK-0887 [SCH032088]), in children with persistent asthma. / Adolescent Asthma
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) at 320 or 640 mcg/day in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma /Adolescent/Adult Asthma
TEVA - A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
TEVA - A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients with Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
Mylan - A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to ADVAIR® DISKUS® Administered Via Oral Inhalation In Adult Asthma Patients. / Adult Asthma
TEVA - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
TEVA - A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered (80 or 160 mcg/Day) delivered via Breath Actuated Inhaler (BAI) in Adolesent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
TEVA - A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 through 11 Years of Age with Persistent Asthma / Pediatric Asthma
TEVA - A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety ofFp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on Highdose Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
BI - A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 μg and 5 μg) administered once daily in the afternoon via Respimat® Inhaler for 12 weeks in patients 1 to 5 years old with persistent asthma. / Pediatric Asthma
GSK - A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma / Adult Asthma
BI - A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 μg and 5 μg once daily) over 12 weeks as add-on controller therapy on top of usual care in adolescents (12 to 17 years old) with severe persistent asthma / Adolescent Asthma
Rigel - A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients with Mild to Moderate Allergic Asthma / Adult Asthma
Cephalon - A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/Kg) Treatment in Patients With Moderate to Severe Asthma / Adult Asthma
BI - A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 μg and 5 μg) delivered via Respimat® inhaler once daily in the evening over 12 weeks as add-on controller therapy on top of usual care in children (6 to 11 years old) with severe persistent asthma / Pediatric Asthma
BI - A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 μg and 5 μg) delivered via Respimat® inhaler once daily in the evening over 48 weeks in children (6 to 11 years old) with moderate persistent asthma / Pediatric Asthma
GSK - A randomised, double-blind, double-dummy,placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids / Adult/Adolescent Asthma
GSK - A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy. / Pediatric Asthma
GSK - A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma / Pediatric Asthma
GlaxoSmithKline - A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in thetreatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids / Adult/Adolescent Asthma
Boehringer Ingelheim - A Phase III randomised, doubleblind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily) delivered by the Respimat® inhaler in adolescents (12 to 17 years old) with moderate persistent asthma. / Adolescent Asthma
Lupin - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study to Assess the Efficacy and Safety of Twice Daily Administration of Fluticasone Propionate and Salmeterol Inhalation Powder 100/50 mcg Compared to Administration of ADVAIR DISKUS® 100/50 mcg Twice Daily and Placebo in Patients 12 Years of Age and Older with Reversible Persistent Asthma including a 3-Week Open-Label Extension to Assess Inhaler Robustness Asthma / Adult/Adolescent Asthma
3M - A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Inhaler and a Symbicort® Reference Inhaler, Each Delivering Budesonide/Formoterol Fumarate (80 μg/4.5 μg) in Adult Subjects With Asthma / Adult Asthma
TEVA - A 12-week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years with Persistent Asthma / Adolescent Asthma
GlaxoSmithKline - A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Propionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhaled corticosteroid and long-acting beta2 agonist./
Adult/Adolescent Asthma
Merck - A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate / formoterol fumarate (MF/F, MK-0887A [SCH418131]), compared with mometasone furoate (MF, MK-0887 [SCH032088]), in children with persistent asthma. / Adolescent Asthma
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) at 320 or 640 mcg/day in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma /Adolescent/Adult Asthma
TEVA - A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
TEVA - A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients with Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
Mylan - A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to ADVAIR® DISKUS® Administered Via Oral Inhalation In Adult Asthma Patients. / Adult Asthma
TEVA - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
TEVA - A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered (80 or 160 mcg/Day) delivered via Breath Actuated Inhaler (BAI) in Adolesent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
TEVA - A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 through 11 Years of Age with Persistent Asthma / Pediatric Asthma
TEVA - A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety ofFp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on Highdose Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
BI - A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 μg and 5 μg) administered once daily in the afternoon via Respimat® Inhaler for 12 weeks in patients 1 to 5 years old with persistent asthma. / Pediatric Asthma
GSK - A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma / Adult Asthma
BI - A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 μg and 5 μg once daily) over 12 weeks as add-on controller therapy on top of usual care in adolescents (12 to 17 years old) with severe persistent asthma / Adolescent Asthma
Rigel - A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients with Mild to Moderate Allergic Asthma / Adult Asthma
Cephalon - A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/Kg) Treatment in Patients With Moderate to Severe Asthma / Adult Asthma
BI - A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 μg and 5 μg) delivered via Respimat® inhaler once daily in the evening over 12 weeks as add-on controller therapy on top of usual care in children (6 to 11 years old) with severe persistent asthma / Pediatric Asthma
BI - A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 μg and 5 μg) delivered via Respimat® inhaler once daily in the evening over 48 weeks in children (6 to 11 years old) with moderate persistent asthma / Pediatric Asthma
GSK - A randomised, double-blind, double-dummy,placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids / Adult/Adolescent Asthma
GSK - A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy. / Pediatric Asthma
GSK - A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma / Pediatric Asthma
GlaxoSmithKline - A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in thetreatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids / Adult/Adolescent Asthma
Boehringer Ingelheim - A Phase III randomised, doubleblind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily) delivered by the Respimat® inhaler in adolescents (12 to 17 years old) with moderate persistent asthma. / Adolescent Asthma
GlaxoSmithKline - A Randomized, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents. / Adult/Adolescent Asthma
GlaxoSmithKline - A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, DoseRanging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist. / Adult/Adosescent Asthma
Boehringer - A Phase II randomised, doubleblind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses 1.25 µg, 2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening in adolescents (12 to 17 yrs old) with moderate persistent asthma. / Adosescent Asthma
AstraZeneca - A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma /
Pediatric Asthma
Novartis - A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control / Adult Asthma
Alcon - Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis / Adult Adolescent PAR
Boehringer Ingelheim - A Phase III randomized, doublepblind, placebo-controlled, parallel group trial to evaluate efficacy and safety of tiotropium inhalatino solutin delivered via Respimat® inhaler (5µ/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma / Asthma
GlaxoSmithKline - A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily in the Evening and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma / Asthma
GlaxoSmithKline - A Randomized, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma / Asthma
Schering Plough - A 52 Week Efficacy and Safety Non-Inferiority Study of fluticasone Propionate/Salmeterol 250/50 mcg BID Delivered by Dry Powder Inhaler (DiskusÒ) Versus Mometasone Furoate/Formoterol Fumarate 200/10 mcg BID Delivered by Pressurized Metered-Dose Inhaler In Persistent Asthmatics Previously Treated with Medium doses of Inhaled Glucocorticosteroids / Asthma
Merck - A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma /
Pediatric Asthma
Sanofi-Aventis - A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the eficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80µg bid regimenf for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids / Asthma
Genentech - An Epidemiologic Study of Xolair® (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (Excels) / Asthma
GlaxoSmithKline - A Randomized, Parallel Group, Double-Blind, Comparative Trial assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 years of Age, with Persistent Asthma, who have either a B16-Arg/Arg, a B16-Gly/Gly or a B-16Arg/Gly Genotype and are treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg or Salmeterol DISKUS 50mcg / Adult/Adolescent Asthma
AstraZeneca - A 12-Week, Randomized, Double-Blind, Double-Dummy Placebo and Active-Controlled Study of SYMBICORT® pMDI Administered Once Daily in Adults and Adolescents with Asthma / Adult Asthma
GlaxoSmithKline - A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, DoseRanging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist. / Adult/Adosescent Asthma
Boehringer - A Phase II randomised, doubleblind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses 1.25 µg, 2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening in adolescents (12 to 17 yrs old) with moderate persistent asthma. / Adosescent Asthma
AstraZeneca - A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma /
Pediatric Asthma
Novartis - A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control / Adult Asthma
Alcon - Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis / Adult Adolescent PAR
Boehringer Ingelheim - A Phase III randomized, doublepblind, placebo-controlled, parallel group trial to evaluate efficacy and safety of tiotropium inhalatino solutin delivered via Respimat® inhaler (5µ/day) over 48 weeks as add-on controller therapy on top of usual care in patients with severe persistent asthma / Asthma
GlaxoSmithKline - A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily in the Evening and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma / Asthma
GlaxoSmithKline - A Randomized, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma / Asthma
Schering Plough - A 52 Week Efficacy and Safety Non-Inferiority Study of fluticasone Propionate/Salmeterol 250/50 mcg BID Delivered by Dry Powder Inhaler (DiskusÒ) Versus Mometasone Furoate/Formoterol Fumarate 200/10 mcg BID Delivered by Pressurized Metered-Dose Inhaler In Persistent Asthmatics Previously Treated with Medium doses of Inhaled Glucocorticosteroids / Asthma
Merck - A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma /
Pediatric Asthma
Sanofi-Aventis - A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the eficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80µg bid regimenf for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids / Asthma
Genentech - An Epidemiologic Study of Xolair® (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (Excels) / Asthma
GlaxoSmithKline - A Randomized, Parallel Group, Double-Blind, Comparative Trial assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 years of Age, with Persistent Asthma, who have either a B16-Arg/Arg, a B16-Gly/Gly or a B-16Arg/Gly Genotype and are treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg or Salmeterol DISKUS 50mcg / Adult/Adolescent Asthma
AstraZeneca - A 12-Week, Randomized, Double-Blind, Double-Dummy Placebo and Active-Controlled Study of SYMBICORT® pMDI Administered Once Daily in Adults and Adolescents with Asthma / Adult Asthma
Pfizer/Altana - A 24 week, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Roflumilast (250mcg or 500 mcg) Daily in Patients with Asthma / Adult Asthma
Glaxo SmithKline - A Multi-Center,Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200 mcg QD versus Montelukast 10 mg QD in
Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis who are Receiveing Concurrent Open-Lable Advair Diskus 100/50 mcg BID. / Adult Asthma
Aventis Pharmaceuticals Inc. - A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess The Efficacy and Safety of exofenadine 120 MG BID in Subjects with Mild to Moderate Persistent Asthma. / Asthma
AstraZeneca - “A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort™ (80/4/5 mcg) versus its Mono-Products (budesonide and formoterol) in Children (> 6 Years of Age) and Adults with Asthma” / Adult/Adolescent Asthma
Aventis Pharmaceuticals Inc. - “A Phase-III Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Efficacy, Safety and Dose-Response Study of Ciclesonide Metered Dose Inhaler 100 ug/Day, 200 ug/Day and 400 ug/Day (ex-valve) Administered Once Daily for 12 weeks is the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.” /Adult/Adolescent Asthma
GlaxoSmithKline - “A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthmas Control in Adolescents and Adults Receiving Either Fluticasone Proprionate/Salmeterol DISKUS Comination Product 100/50 mcg BID, Fluticasone Proprionate DISKUS 100 mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID or Oral Montelukast 10 mg QD.” / Adult/Adolescent Asthma
Schering Plough - “Placebo-Controlled Efficacy and Safety Study of a Once Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Power in Subjects with Asthma who were Previously Maintained on Inhaled Corticosteroids.” / Asthma
Altana - “12 week Treatment with 250 ug Roflumilast vs. Placebo in Patients with Asthma” / Asthma
Baker Norton - “Chronic-Dose Comparison of the Efficacy and Safety of Albuterol-HFA-MDI (Salamol™), Albuterol-HFA-BOI (Salamol Easi-Breathe™) and Proventil ® HFA in Mild to Moderate Asthmatics.” / Asthma
Merck and Co, Inc. - “A Multicenter, Double-Blind, Randomized Study Comparing the Clinical Effects of Concomitant Montelukast+Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients With Chronic Asthma” / Asthma
1167-BRON - A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate Versus Placebo in Pediatric Patients with Symptomatic Asthma" / Pediatric Asthma
Glaxo Wellcome Inc. - “Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone” / Adult/Adolescent Asthma
Glaxo-Wellcome, Inc. - “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, 12-week Study of Fluticasone Propionate 44mcg BID and 88mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma age 6 months to 23 months” / Pediatric Asthma
Glaxo Wellcome, Inc. - “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44-mcg BID and 88mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask In Subjects with Asthma Age 24 Months to 47 Months” / Pediatric Asthma
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Effect on Linear Growth of Montelukast With Placebo and Inhaled Beclomethasone in Pediatric Patients (Prepubertal, Tanner Stage I)With Mild Asthma” / Pediatric Asthma
Glaxo Wellcome Inc. - "A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg BID via the DISKUS Inhaler vs. Oral Montelukast 10mg QD in Adolescents and Adults with Persistent Asthma” / Adult/Adolescent Asthma
3M 1343-BRON - “A 12-Week Comparison of Daily Doses of 100 mcg and 200mcg of HFA-134a Beclomethasone Dipropionate in the Autohaler Device vs. Placebo in Pediatric Patients with Symptomatic Asthma” / Pediatric Asthma
Glaxo Wellcome Inc. - “A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 12 Week Active Control Comparison of Salmeterol/Fluticasone Propionate Combination Product (50/100mcg BID) via the DISKUS inhaler with Fluticasone Propionate (100mcg BID) via the DISKUS plus Oral Montelukast (10mg QD) in Adults and Adolescents with Persistent Asthma Experiencing Symptoms on Inhaled Corticosteroid Therapy” / Adult/Adolescent Asthma
Glaxo SmithKline - A Multi-Center,Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200 mcg QD versus Montelukast 10 mg QD in
Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis who are Receiveing Concurrent Open-Lable Advair Diskus 100/50 mcg BID. / Adult Asthma
Aventis Pharmaceuticals Inc. - A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess The Efficacy and Safety of exofenadine 120 MG BID in Subjects with Mild to Moderate Persistent Asthma. / Asthma
AstraZeneca - “A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort™ (80/4/5 mcg) versus its Mono-Products (budesonide and formoterol) in Children (> 6 Years of Age) and Adults with Asthma” / Adult/Adolescent Asthma
Aventis Pharmaceuticals Inc. - “A Phase-III Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Efficacy, Safety and Dose-Response Study of Ciclesonide Metered Dose Inhaler 100 ug/Day, 200 ug/Day and 400 ug/Day (ex-valve) Administered Once Daily for 12 weeks is the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.” /Adult/Adolescent Asthma
GlaxoSmithKline - “A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthmas Control in Adolescents and Adults Receiving Either Fluticasone Proprionate/Salmeterol DISKUS Comination Product 100/50 mcg BID, Fluticasone Proprionate DISKUS 100 mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID or Oral Montelukast 10 mg QD.” / Adult/Adolescent Asthma
Schering Plough - “Placebo-Controlled Efficacy and Safety Study of a Once Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Power in Subjects with Asthma who were Previously Maintained on Inhaled Corticosteroids.” / Asthma
Altana - “12 week Treatment with 250 ug Roflumilast vs. Placebo in Patients with Asthma” / Asthma
Baker Norton - “Chronic-Dose Comparison of the Efficacy and Safety of Albuterol-HFA-MDI (Salamol™), Albuterol-HFA-BOI (Salamol Easi-Breathe™) and Proventil ® HFA in Mild to Moderate Asthmatics.” / Asthma
Merck and Co, Inc. - “A Multicenter, Double-Blind, Randomized Study Comparing the Clinical Effects of Concomitant Montelukast+Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients With Chronic Asthma” / Asthma
1167-BRON - A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of HFA-134a Beclomethasone Dipropionate Versus Placebo in Pediatric Patients with Symptomatic Asthma" / Pediatric Asthma
Glaxo Wellcome Inc. - “Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone” / Adult/Adolescent Asthma
Glaxo-Wellcome, Inc. - “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, 12-week Study of Fluticasone Propionate 44mcg BID and 88mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma age 6 months to 23 months” / Pediatric Asthma
Glaxo Wellcome, Inc. - “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, 12-Week Study of Fluticasone Propionate 44-mcg BID and 88mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask In Subjects with Asthma Age 24 Months to 47 Months” / Pediatric Asthma
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Effect on Linear Growth of Montelukast With Placebo and Inhaled Beclomethasone in Pediatric Patients (Prepubertal, Tanner Stage I)With Mild Asthma” / Pediatric Asthma
Glaxo Wellcome Inc. - "A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg BID via the DISKUS Inhaler vs. Oral Montelukast 10mg QD in Adolescents and Adults with Persistent Asthma” / Adult/Adolescent Asthma
3M 1343-BRON - “A 12-Week Comparison of Daily Doses of 100 mcg and 200mcg of HFA-134a Beclomethasone Dipropionate in the Autohaler Device vs. Placebo in Pediatric Patients with Symptomatic Asthma” / Pediatric Asthma
Glaxo Wellcome Inc. - “A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 12 Week Active Control Comparison of Salmeterol/Fluticasone Propionate Combination Product (50/100mcg BID) via the DISKUS inhaler with Fluticasone Propionate (100mcg BID) via the DISKUS plus Oral Montelukast (10mg QD) in Adults and Adolescents with Persistent Asthma Experiencing Symptoms on Inhaled Corticosteroid Therapy” / Adult/Adolescent Asthma
Zeneca, Inc. - “A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Determine the Effect of Oral Zafirlukast (ACCOLATE™) when Dosed with Simplified Patient Instructions in Patients Receiving ß2-agonist in Combination with Inhaled Corticosteroids” / Asthma
Merck and Co., Inc. - “A Multicenter, Double-Blind, Placebo-Controlled Study of the Clinical Effect of Nebulized L-808,065 in Patients with Chronic Asthma" / Asthma
Glaxo Wellcome - “A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) with Oral Montelukast (10mg QD) in Subjects with Persistent Asthma Symptomatic on Concomitant Inhaled Corticosteroid Therapy" / Asthma
Schering-Plough - "Placebo-Controlled Efficacy and Safety Study with Long-Term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists" / Asthma
Schering Plough - “A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Budesonide DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids” / Asthma
Merck, Inc. - “A Multicentered, Double-Blind, Randomized Study Comparing the Clinical Effect of Concomitant Montelukast+Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients with Chronic Asthma, open label extension" / Asthma
Merck, Inc. - “A Multicentered, Double-Blind, Randomized Study Comparing the Clinical Effect of Concomitant Montelukast+Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients with Chronic Asthma" / Asthma
Schering Plough - “One Year, Double-Blind Study of the Effects of Mometasone Furoate Dry Powder Inhaler (MF DPI) vs. Placebo on Growth of Children with Asthma” / Pediatric Asthma
Novartis - “A Phase III, 7-month, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial with a 5-month Open-Label Extension Period to Assess Safety and Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 years ) with Allergic Asthma Requiring Daily Treatment with Inhaled Corticosteroids” / Pediatric Asthma
Merck & Company - Open Label Extension “A Multicenter, Double-Blind, Randomized, Parallel-Group Chronic Asthma Study Comparing Montelukast with Placebo in Two to Five-Year-Old Patients" / Pediatric Asthma
Zeneca Pharmaceuticals - "A Dose-ranging, Safety, and Efficacy Trial with Zafirlukast (ACCOLATE Ô) in the Treatment of Pediatric Subjects with Mild to Moderate Asthma; Up to a 52 Week Open Label Safety Extension" / Pediatric Asthma
Schering-Plough - "Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Compared to Beclomethasone Dipropionate (Vanceril) in the Treatment of Asthma in Patient Previously Maintained on Inhaled Corticosteroids" / Asthma
Dey Laboratories - "A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Low-Dose Albuterol Sulfate Inhalation Solution for Pediatric Subjects with Asthma" / Pediatric Asthma
Astra, USA - "A Study of the Effect of Early Intervention with Long-Term Inhaled Budesonide (Pulmicort® Turbuhaler®) in Newly Diagnosed Asthma" / Asthma
Merck and Co., Inc. - “A Multicenter, Double-Blind, Placebo-Controlled Study of the Clinical Effect of Nebulized L-808,065 in Patients with Chronic Asthma" / Asthma
Glaxo Wellcome - “A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) with Oral Montelukast (10mg QD) in Subjects with Persistent Asthma Symptomatic on Concomitant Inhaled Corticosteroid Therapy" / Asthma
Schering-Plough - "Placebo-Controlled Efficacy and Safety Study with Long-Term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists" / Asthma
Schering Plough - “A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Budesonide DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids” / Asthma
Merck, Inc. - “A Multicentered, Double-Blind, Randomized Study Comparing the Clinical Effect of Concomitant Montelukast+Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients with Chronic Asthma, open label extension" / Asthma
Merck, Inc. - “A Multicentered, Double-Blind, Randomized Study Comparing the Clinical Effect of Concomitant Montelukast+Loratadine with Montelukast, Loratadine, and Inhaled Beclomethasone in Patients with Chronic Asthma" / Asthma
Schering Plough - “One Year, Double-Blind Study of the Effects of Mometasone Furoate Dry Powder Inhaler (MF DPI) vs. Placebo on Growth of Children with Asthma” / Pediatric Asthma
Novartis - “A Phase III, 7-month, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial with a 5-month Open-Label Extension Period to Assess Safety and Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 years ) with Allergic Asthma Requiring Daily Treatment with Inhaled Corticosteroids” / Pediatric Asthma
Merck & Company - Open Label Extension “A Multicenter, Double-Blind, Randomized, Parallel-Group Chronic Asthma Study Comparing Montelukast with Placebo in Two to Five-Year-Old Patients" / Pediatric Asthma
Zeneca Pharmaceuticals - "A Dose-ranging, Safety, and Efficacy Trial with Zafirlukast (ACCOLATE Ô) in the Treatment of Pediatric Subjects with Mild to Moderate Asthma; Up to a 52 Week Open Label Safety Extension" / Pediatric Asthma
Schering-Plough - "Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Dry Powder Compared to Beclomethasone Dipropionate (Vanceril) in the Treatment of Asthma in Patient Previously Maintained on Inhaled Corticosteroids" / Asthma
Dey Laboratories - "A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Low-Dose Albuterol Sulfate Inhalation Solution for Pediatric Subjects with Asthma" / Pediatric Asthma
Astra, USA - "A Study of the Effect of Early Intervention with Long-Term Inhaled Budesonide (Pulmicort® Turbuhaler®) in Newly Diagnosed Asthma" / Asthma
Glaxo Wellcome - "A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50MCG BID and Fluticasone Propionate 250MCG BID Individually and in Combination and Placebo in Subjects with Asthma" / Asthma
SmithKline Beecham - "A Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability and Efficacy of Oral SB 205312 in Pediatric Patients with Mild to Moderate Asthma" / Pediatric Asthma
Glaxo Wellcome - "A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial of the Effects of Twelve Week Courses of 50mcg and 25mcg Salmeterol Powder Via the DiskusÔ BID vs. Ventolin Rotacaps® 200mcg QID vs. Placebo in Pediatric Subjects Aged 4-11 Years with Mild to Moderate Asthma" / Pediatric Asthma
SmithKline Beecham - "A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Oral Twice-Daily Administration of SB 205312 in Pediatric Patients with Mild to Moderate Asthma"/ Pediatric Asthma
Glaxo Wellcome - "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Trial Evaluating Safety and Efficacy of Salmeterol Xinafoate and Fluticasone Propionate Individually and in Combination in Patients with Asthma" / Asthma
Merck, Inc., long term - "A Multiple, Double-Blind, Randomized, Parallel-Group Study Comparing MK-0476 to Placebo in 6 to 14-Year-Old Patients with Chronic Asthma" / Pediatric Asthma
Astra USA, Inc. - "A Study of Four Dose Regimens of Budesonide (Pulmicort) Nebulizing Suspension and Placebo in Asthmatic Children Aged Eight Years and Younger" / Pediatric Asthma
Dey Laboratories - "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Safety and Efficacy of Cromolyn Sodium Inhalation Solution in an Isotonic Formulation in Pediatrics" / Pediatric Asthma
Fisons Corporation - "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Group Comparative Study of the Safety and Effectiveness of Tilade Metered Dose Inhaler Administered as 3.5 mg QID or 7 mg BID in the Treatment of Children with Asthma Exacerbated by Ragweed Pollen" / Pediatric Asthma
Glaxo, Inc. - "A Randomized, Double-Blind, Parallel-Group, Clinical Trial of the Effects of Twelve-Month Courses of Salmeterol Xinafoate Rotadisk vs. Placebo on Methacholine-Induced Bronchial Hyper responsiveness in Adolescent and Adult Patients with Chronic Mild-to-Moderate Asthma" / Adult/Adolescent Asthma
Glaxo, Inc. - "A Randomized, Double-Blind, Parallel Group, Comparative Trial Assessing the Long-Term Safety of Inhaled Fluticasone Propionate Rotadisks via Diskhaler 50 mcg BID and 100 mcg BID vs. Placebo in Patients Aged 4 to 11 Years with Mild to Moderate Chronic Asthma" / Pediatric Asthma
Glaxo, Inc. - "A Randomized, Double-Blind, Comparative Trial of Two Doses of Inhaled Fluticasone Propionate vs. Placebo in Patients Aged 4 to 11 Years with Mild to Moderate Chronic Asthma" / Pediatric Asthma
Glaxo, Inc. - "A Randomized, Double-Blind, Dose-Ranging Trial of Three Doses of Inhaled Fluticasone Propionate vs. Placebo in Adult and Adolescent Patients with Mild to Moderate Asthma" / Adult/Adolescent Asthma
Allergic Rhinitis Research Experience
Allergy Therapeutics A Randomized, Double-blind, Placebo Controlled clinical trial to evaluate the Efficacy and Safety of PQ Grass in Subjects with Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis induced by Grass Pollen exposure / Adult SAR
Glenmark - A Double-Blind, Randomized Parallell-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Comination GSP 301 nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Glenmark - A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older) /Adult/Adolescent SAR
Circassia - A Combined Phase 2b/3 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects with Grass Pollen-Induced Allergic Rhinitis, with or without Conjunctivitis / Adult/Adolescent SAR
Merck - A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in children With A History of Ragweed-Induced rhinoconjunctivitis With or Without Asthma./ Peds Rhinoconjunctivitis
Circassia - A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis / Adult Rhinoconjunctivitis
PerrigoPRG - A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the safety and bioequivalence of Perrigo UK FINCO's Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray 137mcg/50mcg per actuation compared with Meda Pharmaceuticals Inc.'s Dymista® (Azelastine Hydrochloride/Fluticasone Propionate) Nasal Spray 137mcg/50mcg per actuation in the relief of seasonal allergic rhinitis (SAR) symptoms./ Adult/Adolescent SAR
GSK - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR). / Adult SAR
Merck - A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced AllergicRhinitis/Rhinoconjunctivitis With or Without Asthma / Adult/Child SLIT PAR
Merck - A 28-Day Study Evaluating the Safety of Short Ragweed (Ambrosia artemisifolia) Allergy Immunotherapy Tablet (SCH 39641) Treatment in Subjects 18 years of age and older (Phase 2, Protocol No. P05751) / Adult SAR
Merck - A Multicente, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum prantense) Sublingual Tablet (SCH 697243) in subjects at Least 5 Years of Age, with a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma./ Pediatric SAR
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Finding Study To Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Pediatric Subjects (6 to 11 years of age) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Schering Plough - A Multicenter, Double-Blind, Random ized, Placebo-Controlled, Parallel-Group Sutdy of Ragweed Sublingual Tablet in Adult Subjects with A History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma / Ragweed SLIT
Stallergene - A randomized, double-blind, placebo-controlled, multi-center, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from grass pollen rhinoconjunctivitis. / Adult SLIT
Greer Labs - Parallel, Randomized, Double blind Placebo Controlled Trial in Adults for the Sublingual Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused by Ragweed Pollen / SAR
Schering Plough - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With A History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / Pediatric Observation SAR
Alcon - Safety and Efficacy of Olopatadine HCI Nasal Spray in 6-11 Year Old Patients / Pediatric SAR
GlaxoSmithKline - A comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis / SAR
ALK/Abello (GRAZAX) - A phase III trial assessing the efficacy and safety of Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis with or without asthma / SAR
Alcon - Safety Study of Olopatadine Nasal Spray / PAR
ITGI - A Double-blind, Placebo-controlled, Randomized, Parallel-group Mutlicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in subjects with Symptomatic Seasonal Allergic Rhinitis / Fall Allergy
Altana - A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinits (SAR) in Patients 6 to 11 Years of Age / Pediatric SAR
Dynavax/CRN - A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Subcutaneously Administered TOLAMBA™ in Ragweed-Allergic Adults / Fall Ragweed
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intrannasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 2 weeks in Adult and Adolescent Subjects ≥12 Years of Age with Seasonal Allergic Rhinitis (SAR) / Fall SAR
Clay-Park Labs, Inc. - An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Demonstrate The Safety and Bioequivalence of Triaminolone Acetonide Nasal Spray [AGIS Industries (1983) LTD.] Compared with Nasacort AQ® Nasal Spray 55 Mcg (Aventis) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis (SAR). / SAR
ITGI, Inc. - Efficay and Safety of Desloratadine, Fexofenadine 180 mg. and Placebo in the Treatment of Subjects with Symptomatic Seasonal allergic Rhinitis (SAR) / Adult SAR
ALTANA Pharma - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200µg, 100µg,or 25µg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age / Pediatric PAR
DYNAVAX Technologies - A Phase II Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults / Adult Ragweed
Merck & Co., Inc. - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis / Adult/Adolescent PAR
Glenmark - A Double-Blind, Randomized Parallell-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Comination GSP 301 nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Glenmark - A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older) /Adult/Adolescent SAR
Circassia - A Combined Phase 2b/3 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects with Grass Pollen-Induced Allergic Rhinitis, with or without Conjunctivitis / Adult/Adolescent SAR
Merck - A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in children With A History of Ragweed-Induced rhinoconjunctivitis With or Without Asthma./ Peds Rhinoconjunctivitis
Circassia - A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis / Adult Rhinoconjunctivitis
PerrigoPRG - A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the safety and bioequivalence of Perrigo UK FINCO's Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray 137mcg/50mcg per actuation compared with Meda Pharmaceuticals Inc.'s Dymista® (Azelastine Hydrochloride/Fluticasone Propionate) Nasal Spray 137mcg/50mcg per actuation in the relief of seasonal allergic rhinitis (SAR) symptoms./ Adult/Adolescent SAR
GSK - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR). / Adult SAR
Merck - A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced AllergicRhinitis/Rhinoconjunctivitis With or Without Asthma / Adult/Child SLIT PAR
Merck - A 28-Day Study Evaluating the Safety of Short Ragweed (Ambrosia artemisifolia) Allergy Immunotherapy Tablet (SCH 39641) Treatment in Subjects 18 years of age and older (Phase 2, Protocol No. P05751) / Adult SAR
Merck - A Multicente, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum prantense) Sublingual Tablet (SCH 697243) in subjects at Least 5 Years of Age, with a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma./ Pediatric SAR
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Finding Study To Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Pediatric Subjects (6 to 11 years of age) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Schering Plough - A Multicenter, Double-Blind, Random ized, Placebo-Controlled, Parallel-Group Sutdy of Ragweed Sublingual Tablet in Adult Subjects with A History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma / Ragweed SLIT
Stallergene - A randomized, double-blind, placebo-controlled, multi-center, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from grass pollen rhinoconjunctivitis. / Adult SLIT
Greer Labs - Parallel, Randomized, Double blind Placebo Controlled Trial in Adults for the Sublingual Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused by Ragweed Pollen / SAR
Schering Plough - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With A History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / Pediatric Observation SAR
Alcon - Safety and Efficacy of Olopatadine HCI Nasal Spray in 6-11 Year Old Patients / Pediatric SAR
GlaxoSmithKline - A comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis / SAR
ALK/Abello (GRAZAX) - A phase III trial assessing the efficacy and safety of Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis with or without asthma / SAR
Alcon - Safety Study of Olopatadine Nasal Spray / PAR
ITGI - A Double-blind, Placebo-controlled, Randomized, Parallel-group Mutlicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in subjects with Symptomatic Seasonal Allergic Rhinitis / Fall Allergy
Altana - A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinits (SAR) in Patients 6 to 11 Years of Age / Pediatric SAR
Dynavax/CRN - A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Subcutaneously Administered TOLAMBA™ in Ragweed-Allergic Adults / Fall Ragweed
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intrannasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 2 weeks in Adult and Adolescent Subjects ≥12 Years of Age with Seasonal Allergic Rhinitis (SAR) / Fall SAR
Clay-Park Labs, Inc. - An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Demonstrate The Safety and Bioequivalence of Triaminolone Acetonide Nasal Spray [AGIS Industries (1983) LTD.] Compared with Nasacort AQ® Nasal Spray 55 Mcg (Aventis) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis (SAR). / SAR
ITGI, Inc. - Efficay and Safety of Desloratadine, Fexofenadine 180 mg. and Placebo in the Treatment of Subjects with Symptomatic Seasonal allergic Rhinitis (SAR) / Adult SAR
ALTANA Pharma - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200µg, 100µg,or 25µg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age / Pediatric PAR
DYNAVAX Technologies - A Phase II Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults / Adult Ragweed
Merck & Co., Inc. - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis / Adult/Adolescent PAR
Schering Plough - Comparison of Sedation and Performance Impairment Measures in Untreated Healthy and Atopic symptomatic Subjects Receiving Claitin, Benadryl, or Placebo / Adult SAR
Integrated Therapeutics Group, Inc. - Preference Evaluation of Clarinex Tablets vs.
Zyretec Tablets in Subjects with Symptomatic Allergic Rhinitis (AR) / Adult Allergic Rhinitis
Integrated Therapeutics Group, Inc.- Efficacy and Safety of Clarinex in Subjects with Allergic Airway Disease during the Pollen Season / Allergic Airway Disease
Aventis Pharmaceuticals Inc. - “A multicenter, double-blind, randomized, parallel study comparing the efficacy and safety of fexofenadine 12mg Bid, fexotenadine 240mg OQ, and placebo in subjects with perennial allergic rhinitis” / PAR
Roxanne - “A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study Comparing the Efficacy and Safety of Generic Fluticasone Propionate Aqueous Nasal Spray Versus FLONASE® NasalSpray Versus Placebo Basal Spray in Subjects with Seasonal Allergic Rhinitis.” / SAR
MURO (Day in the Park) - “Evaluation of the Onset of Action (Day-in-the-Park) of A Single Dose of 400 mg Loteprednol Etabonate Nasal Spray in Adults and Adolescents with Ragweed-Induced Seasonal Allergic Rhinitis (“Intermittent rhinitis”) Multi-center, randomized, double-blind, placebo-controlled, parallel group study”. / Adult/Adolescent Ragweed
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 2 Through 14 Years With Seasonal Allergic Rhinitis” / Pediatric SAR
Muro Pharmaceutical, Inc. - “Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study of Four Doses of Loteprednol Etabonate Nasal Spray (100mcg, 200mcg, 400mcg, and 800mcg) with Flonase (200mcg) as an Open Active-Control in the Treatment of Adult and Adolescents with Allergic Rhinitis Induced by Grass Pollen” / Adult/Adolescent Allergic Rhinitis
Pfizer Inc. - “A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine-Pseudoephedrine vs. Loratadine-Pseudoephedrine (Claritin-D® 12 Hour) vs. Placebo in the Treatment of Subjects Twelve Years and Older with Seasonal Allergic Rhinitis” / Adult/Adolescent SAR
Hoechst Marion Roussel - “A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCI Tablets 30 mg Twice a Day in Pediatric Subjects (6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis" / Pediatric SAR
Schering-Plough Research Institute - “Efficacy and Safety of SCH 483 5/240 mg and SCH 483 6/240 mg, Compared to Desloratadine 5 mg and Pseudoephedrine 240 mg QD Sustained Release, in the Treatment of Subjects With Seasonal Allergic Rhinitis” / SAR
UCB Pharma, Inc. - “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study Comparing the Efficacy and Safety of Three Doses (4 mg, 15 mg, and 80 mg) of ucb 28754 (efletirizine dihydrochloride), Administrated Twice a Day for 7 Days, to Placebo in Adult Outpatients with Seasonal Allergic Rhinitis caused by Ragweed Pollen” / Adult SAR
Glaxo Wellcome Inc. - “A Double-Blind, Double Dummy, Randomized, Parallel Group Comparison of 200 mcg Fluticasone Propionate Aqueous Nasal Spray, Placebo and 10 mg Encapsulated Loratadine Administered (No More than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis" / SAR
Integrated Therapeutics Group, Inc. - Preference Evaluation of Clarinex Tablets vs.
Zyretec Tablets in Subjects with Symptomatic Allergic Rhinitis (AR) / Adult Allergic Rhinitis
Integrated Therapeutics Group, Inc.- Efficacy and Safety of Clarinex in Subjects with Allergic Airway Disease during the Pollen Season / Allergic Airway Disease
Aventis Pharmaceuticals Inc. - “A multicenter, double-blind, randomized, parallel study comparing the efficacy and safety of fexofenadine 12mg Bid, fexotenadine 240mg OQ, and placebo in subjects with perennial allergic rhinitis” / PAR
Roxanne - “A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study Comparing the Efficacy and Safety of Generic Fluticasone Propionate Aqueous Nasal Spray Versus FLONASE® NasalSpray Versus Placebo Basal Spray in Subjects with Seasonal Allergic Rhinitis.” / SAR
MURO (Day in the Park) - “Evaluation of the Onset of Action (Day-in-the-Park) of A Single Dose of 400 mg Loteprednol Etabonate Nasal Spray in Adults and Adolescents with Ragweed-Induced Seasonal Allergic Rhinitis (“Intermittent rhinitis”) Multi-center, randomized, double-blind, placebo-controlled, parallel group study”. / Adult/Adolescent Ragweed
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 2 Through 14 Years With Seasonal Allergic Rhinitis” / Pediatric SAR
Muro Pharmaceutical, Inc. - “Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study of Four Doses of Loteprednol Etabonate Nasal Spray (100mcg, 200mcg, 400mcg, and 800mcg) with Flonase (200mcg) as an Open Active-Control in the Treatment of Adult and Adolescents with Allergic Rhinitis Induced by Grass Pollen” / Adult/Adolescent Allergic Rhinitis
Pfizer Inc. - “A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine-Pseudoephedrine vs. Loratadine-Pseudoephedrine (Claritin-D® 12 Hour) vs. Placebo in the Treatment of Subjects Twelve Years and Older with Seasonal Allergic Rhinitis” / Adult/Adolescent SAR
Hoechst Marion Roussel - “A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCI Tablets 30 mg Twice a Day in Pediatric Subjects (6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis" / Pediatric SAR
Schering-Plough Research Institute - “Efficacy and Safety of SCH 483 5/240 mg and SCH 483 6/240 mg, Compared to Desloratadine 5 mg and Pseudoephedrine 240 mg QD Sustained Release, in the Treatment of Subjects With Seasonal Allergic Rhinitis” / SAR
UCB Pharma, Inc. - “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study Comparing the Efficacy and Safety of Three Doses (4 mg, 15 mg, and 80 mg) of ucb 28754 (efletirizine dihydrochloride), Administrated Twice a Day for 7 Days, to Placebo in Adult Outpatients with Seasonal Allergic Rhinitis caused by Ragweed Pollen” / Adult SAR
Glaxo Wellcome Inc. - “A Double-Blind, Double Dummy, Randomized, Parallel Group Comparison of 200 mcg Fluticasone Propionate Aqueous Nasal Spray, Placebo and 10 mg Encapsulated Loratadine Administered (No More than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis" / SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis-Fall Study” / SAR
Warner Lambert - “Clinical Efficacy Comparison of Benadryl, Claritin and Placebo in Seasonal Allergic Rhinitis” / SAR
Schering Plough - “The Safety and Efficacy of ClaritinÒ vs. Fexofenadine in the Treatment of Seasonal Allergic Rhinitis: A Double-Blind Comparison with Crossover Treatment of Non-responders" / SAR
Glaxo Wellcome - "Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, Parallel Group Comparison of Fluticasone Propionate Aqueous Nasal Spray and Triamcinolone Acetonide Aqueous Nasal Spray for Four Weeks in Subjects with Seasonal Allergic Rhinitis" / SAR
Sepracor - “The Evaluation of Three Norastemizole Doses (15mg, 30mg, 45mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis. A Multi-Dose, Double-Dummy, Double-Blind, Placebo-Controlled, Parallel Group Study" / SAR
Hoescht Marion Roussel - "A Double-Blind Randomized, Placebo-Controlled, Parallel Study Comparing the Efficacy and Safety of Three Dosage Strengths of Fexofenadine HCl (15, 30, 60 MG BID) in Pediatric Patients (Ages 6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis" / Pediatric SAR
Schering-Plough Corporation - "One-Year, Double-Blind Study of the Effects of Mometasone Furoate Nasal Spray vs. Placebo on Growth of Children with Perennial Rhinitis" / Pediatric PAR
Integrated Therapeutics/Schering - "Safety and Efficacy of Claritin-D 24 Hour vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis (SAR)" / SAR
Schering-Plough - "Safety and Efficacy of Mometasone Furoate Nasal Spray vs. Placebo in the Treatment of Elderly Patients with Perennial Rhinitis" / Adult/Elderly PAR
Schering-Plough - "A Long Term Safety Study of SCH 32088 vs. Nasacort in Perennial Rhinitis" / PAR
Muro Pharmaceuticals - "A Dose Response Study of ucb 28754 in Male and Female Patients with Seasonal Allergic Rhinitis" / SAR
Astra USA - "A Double-Blind, Randomized, Parallel Group Comparison of Four Doses of Rhinocort Aqua Pump Spray (budesonide) and Placebo in the Treatment of Adults and Children with Seasonal Allergic Rhinitis" / Adult/Pediatric SAR
Schering-Plough - "Prophylactic Treatment of Seasonal Allergic Rhinitis with Mometasone Furoate Aqueous Nasal Spray" / SAR
Schering-Plough Research - "Efficacy of Claritin vs. Seldane versus Placebo upon Awakening in Spring Allergic Rhinitis (SAR)" / SAR
Schering-Plough Research - "Long Term Safety of SCH 32088 in Perennial Rhinitis" / PAR
Schering-Plough Research - "Efficacy and Safety of SCH 32088 in Perennial Rhinitis" / PAR
Warner Lambert - “Clinical Efficacy Comparison of Benadryl, Claritin and Placebo in Seasonal Allergic Rhinitis” / SAR
Schering Plough - “The Safety and Efficacy of ClaritinÒ vs. Fexofenadine in the Treatment of Seasonal Allergic Rhinitis: A Double-Blind Comparison with Crossover Treatment of Non-responders" / SAR
Glaxo Wellcome - "Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, Parallel Group Comparison of Fluticasone Propionate Aqueous Nasal Spray and Triamcinolone Acetonide Aqueous Nasal Spray for Four Weeks in Subjects with Seasonal Allergic Rhinitis" / SAR
Sepracor - “The Evaluation of Three Norastemizole Doses (15mg, 30mg, 45mg) and Loratadine When Administered to Subjects with Seasonal Allergic Rhinitis. A Multi-Dose, Double-Dummy, Double-Blind, Placebo-Controlled, Parallel Group Study" / SAR
Hoescht Marion Roussel - "A Double-Blind Randomized, Placebo-Controlled, Parallel Study Comparing the Efficacy and Safety of Three Dosage Strengths of Fexofenadine HCl (15, 30, 60 MG BID) in Pediatric Patients (Ages 6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis" / Pediatric SAR
Schering-Plough Corporation - "One-Year, Double-Blind Study of the Effects of Mometasone Furoate Nasal Spray vs. Placebo on Growth of Children with Perennial Rhinitis" / Pediatric PAR
Integrated Therapeutics/Schering - "Safety and Efficacy of Claritin-D 24 Hour vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis (SAR)" / SAR
Schering-Plough - "Safety and Efficacy of Mometasone Furoate Nasal Spray vs. Placebo in the Treatment of Elderly Patients with Perennial Rhinitis" / Adult/Elderly PAR
Schering-Plough - "A Long Term Safety Study of SCH 32088 vs. Nasacort in Perennial Rhinitis" / PAR
Muro Pharmaceuticals - "A Dose Response Study of ucb 28754 in Male and Female Patients with Seasonal Allergic Rhinitis" / SAR
Astra USA - "A Double-Blind, Randomized, Parallel Group Comparison of Four Doses of Rhinocort Aqua Pump Spray (budesonide) and Placebo in the Treatment of Adults and Children with Seasonal Allergic Rhinitis" / Adult/Pediatric SAR
Schering-Plough - "Prophylactic Treatment of Seasonal Allergic Rhinitis with Mometasone Furoate Aqueous Nasal Spray" / SAR
Schering-Plough Research - "Efficacy of Claritin vs. Seldane versus Placebo upon Awakening in Spring Allergic Rhinitis (SAR)" / SAR
Schering-Plough Research - "Long Term Safety of SCH 32088 in Perennial Rhinitis" / PAR
Schering-Plough Research - "Efficacy and Safety of SCH 32088 in Perennial Rhinitis" / PAR
Fisons Corporation - "A Dose-Ranging, Multi-Center, Double-Blind, Placebo-Controlled, Group Comparative Study of Tipredane Nasal Spray in Seasonal Allergic Rhinitis Caused by Ragweed Pollen" / SAR
Rhone-Poulenc Rorer - "Multicenter, Double-Blind, Parallel Group, Randomized Comparison of Ebastine and Placebo in Children with Perennial Allergic Rhinitis" / Pediatric PAR
Rhone-Poulenc Rorer - "A Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of Nasacort Nasal Inhaler (triamcinolone acetonide) in Patients with Perennial Nonallergic Rhinitis" / PAR
Rhone-Poulenc Rorer - "Multicenter, Double-Blind, Parallel Group, Randomized Comparison of Ebastine and Placebo in Children with Perennial Allergic Rhinitis" / Pediatric PAR
Rhone-Poulenc Rorer - "A Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of Nasacort Nasal Inhaler (triamcinolone acetonide) in Patients with Perennial Nonallergic Rhinitis" / PAR
Device Studies
GlaxoSmithKline - An open-label study to evaluate the correct use of placebo ELLIPTA™ dry powder inhaler (DPI) compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent asthma / Adult/Adolescent Device
Chronic Idiopathic Urticaria
Novartis - A multicenter, randomized, double-blind, placebo- controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines / Chronic Idiopathic Urticaria
ITGI - A Comparitive Double-Blind, Double-Dummy Study of Desloratadine (DL) 5mg Once Daily, Cetirizine 10mg Once Daily, and Placebo Once Daily in Patients with Chronic Idiopathic Urticaria (DIU) / Chronic Idiopathic Urticaria
ITGI - A Comparitive Double-Blind, Double-Dummy Study of Desloratadine (DL) 5mg Once Daily, Cetirizine 10mg Once Daily, and Placebo Once Daily in Patients with Chronic Idiopathic Urticaria (DIU) / Chronic Idiopathic Urticaria
Nasal Polyps treatment
Schering Plough - “Efficacy and Safety of 200 mcg or 400 mcg of Mometasone Furate4 Nasal Spray (MFNS) or Placebo in the Treatment of Nasal Polyps” / Nasal Polyps
Streptococcal Pharyngitis
Hoffmann La-Roche - "A Single-Blind Randomized Comparative Study of Single Dose (IM) Ceftriaxone and Single Dose (IM) Benzathine Penicillin G for the Treatment of Streptococcal Pharyngitis in Children" / Pediatric Streptococcal Pharyngitis
Acute Allergic Conjunctivitis
Akorn, Inc. - "Effects of Naphazoline (0.025%)/ Pheniramine (0.3%) in Combination as Compared to Vehicle Control, Naphazoline (0.025%), and Pheniramine (0.3%) in the Allergen Challenge Model of Acute Allergic Conjunctivitis" / Acute Allergic Conjunctivitis
Alcon Laboratories - "Efficacy and Safety Evaluation of Naphcon-A Ophthalmic Solution in Allergic/Atopic and Nonspecific Conjunctivitis" / Conjunctivitis
Alcon Laboratories - "Efficacy and Safety Evaluation of Naphcon-A Ophthalmic Solution in Allergic/Atopic and Nonspecific Conjunctivitis" / Conjunctivitis
Pneumonia
Rhone-Poulenc Rorer - "Double-Blind, Randomized, Comparative, Multicenter Study of RP-64206 (Sparfloxacin) vs. Cefaclor in the Treatment of Community-Acquired Pneumonia" / Pneumonia
Common Cold
Sandoz Pharmaceuticals - "A Study to Establish the Onset and Duration of Nasal Decongestant Activity with TheraFlu Cough and Cold Medicine in Patients with a Common Cold" / Common Cold